|
|
Slowing Down Your Ejaculation - Condoms, Delay Gels & LotionTopical Anesthetics However, they can cause unwanted side-effects such as complete loss of feeling or numbing of the partner's vagina, or difficulties with erection. A numb vagina may be avoided by using a condom. Premature Ejaculation Treatment - Delay SprayPSD502 may be a quick cure for premature ejaculation....or maybe not.What is PSD502? It's a new formulation of two local anesthetics, lidocaine and prilocaine, which are delivered in carefully controlled quantities by aerosol, developed by Sciele Pharma, Inc. a pharmaceutical company which focuses on developing and marketing branded prescription products to deal with cardiovascular issues, diabetes, problems in women's health, and pediatric issues. This anesthetic spray, designed to delay a man's ejaculation, sounds a bit like an anesthetic lotion for the penis which was produced in the 1970's but never really caught on. However, PSD502 is a new compound manufactured for men with premature ejaculation. It consists of an aerosol spray with which the man can spray a numbing or desensitizing lotion onto his penis a few minutes before intercourse to reduce sensitivity to sexual stimulation. The results show that men who used the spray lasted up to six times longer during sex than men who had not used the spray - but were they satisfied with their orgasm? It's an important question, since men who have used condoms impregnated with local anesthetic or sprays like this generally seem to find that while they do not last much longer during sex, the pleasure of their orgasm is greatly reduced. Older methods of applying the anesthetic seem to include treatments with serious drawbacks - at least, if you see sex as something that is meant to satisfy both partners! This may explain the dilly-dallying around licencing of PSD502 as a delay treatment. However, in one study, the results presented by Professor Wallace Dinsmore apparently showed that PSD502 was very well received and caused few adverse effects, being well tolerated and accepted by the men who took part in the study. We all know that many men want to slow down ejaculation: depending on how you define PE, as many as 75% of men have the problem....and every man who ejaculates too quickly knows what a problem it can be! Despite this, there is no prescription drug approved by the FDA to treat the condition; and a simple solution like a spray on anesthetic would obviously make many men's sexual experiences - not to mention those of their partners - much more enjoyable. But does an anesthesia spray work?The study into the effectiveness of PSD502 in treating premature ejaculation was done with the help of 300 men in four European countries. The average time between penetration and ejaculation was increased to three minutes minute in 90% of the men taking part. But this seems like a very small increases - though some men would undoubtedly have benefited more - and despite the fact that the men's sexual satisfaction rating was correspondingly higher after receiving PSD502, I would be very interested to know how sex actually felt to the men concerned after they had this anesthetic applied to their penis. I believe it would not be as rewarding. So here is the relevant data on quality of orgasm: the number of men who thought they'd had a "good" or "very good" orgasm increased from 20% to over 60% with the drug. So, it seems that the men liked it. But the result of a comparatively small scale trial like this do not really reveal much about the practical application of the system in the real world. For one thing, the conditions under which the drug was applied to the penises of the men before intercourse would no doubt have been very strictly controlled. For another, the men may have reported greater sexual satisfaction simply because they could maintain vaginal penetration and enjoy delays during intercourse, slowing down ejaculation - and that's bound to be a significant thing for a man who is accustomed to ejaculating almost immediately after penetration. As far as side effects were concerned, the study obfuscates by reporting that "only" 2.6% of men reported treatment-related adverse events. These included a case of penile numbness.....as opposed, presumably, to reduced sensitivity. Five men experienced mild adverse effects: one man experienced hypoesthesia (reduced sense of touch or sensation, or a partial loss of sensitivity to sensory stimuli), there were two episodes of erythema, (redness of the skin caused by capillary congestion), one report of burning, and two men lost their erections. PSD502 is a non-ionized combination of lidocaine and prilocaine 2.5 mg in a propellant, designed to be sprayed onto a man's glans only five minutes before sexual intercourse takes place. As a result of its chemical properties the compound penetrates the surface of the penis, thus taking only five minutes before the onset of its action. Maybe the most important aspect of the study is that the drug does not only help the man to last longer - it helps his partner, who may care more about his premature ejaculation than he does. American Urological Association 104th Annual Scientific Meeting: Abstract 1370: Presented April 28, 2009. How to last longer in bed for men !Latest developments around PSD502 Sciele Pharma Inc. announced in July 2009 that another double-blind, placebo-controlled study of their new compound PSD502, designed for for the treatment of premature ejaculation, has fulfilled all the measures needed to regard it as a successful treatment. These measures include standards of Intravginal Ejaculatory Latency Time and the International Index of Sexual Satisfaction. The latest study was conducted on men from the USA, Canada and Europe. Previous research had been conducted on men from Europe, and the results reported in November 2008. Final approval for the product will be sought on the basis of the combined data. The President and Chief Operating Officer
of Sciele Pharma, Ed Schutter, reminded us that if the product gets
FDA
approval, it will be the first prescription treatment in the United
States specifically designed to deal with the common condition of
premature ejaculation. Both the first and second studies showed consistent results. PSD502 showed highly statistically significant improvements from the start of the study in all measures: intra-vaginal ejaculation latency time (IELT), ejaculatory control, sexual satisfaction, and partner satisfaction. More specifically, IELT improved by a factor of six; the IPE domains for ejaculatory control and sexual satisfaction showed a five point increase; and partner satisfaction increased "considerably". All these results were highly statistically significant. Happily, there were no more serious adverse events and overall side effects in the group of men treated with PSD502 than there were in the placebo group. There were no systemic adverse events, although a small number of men experienced a degree of numbness to the penis. This was less than 3% of the cohort. It seems that PSD502 may be of some benefit to both men with rapid ejaculation and their partners: especially since the product can be used on an "on-demand" basis. It only takes five minutes before it becomes effective, and there must be many men who would like the product to be licensed as soon as possible! (Up to 75% of men ejaculate too rapidly for their liking or their partner's sexual satisfaction.) This drug certainly seems to have more promise than most developments in the field of premature ejaculation treatment. However, I'd also like to remind you that not all sexual pleasure is down to your ability to develop sufficient staying power and knowing how to last longer in bed. Pleasing a woman
sexually requires a degree of skill and finesse which goes well beyond
the ability to make love for ages (to sustain a high IELT, in the terms
of the boffins). It's worthwhile checking out this
link for more information on a subset of sexual skills which are
necessary for all men who (1) wish to be competent lovers and (2) have a
desire to know how to delay ejaculation and please a
woman in bed. The Company's lead development asset PSD502, a treatment for premature ejaculation, was licensed to Shionogi Pharma Inc (formerly Sciele Pharma Inc) on a global basis in May 2009. Shionogi is today responsible for all aspects of regulatory filing and commercial development. To date the regulatory development of PSD502 has been behind expectations... given that commercialization is controlled by Shionogi, the timing and quantum of income from this agreement is uncertain...The Company has recently sought the opinion of independent regulatory experts on the work required and likelihood of achieving a regulatory approval of PSD502, particularly in the EU. As a result, the Company confirms its confidence that once filed a dossier would be approved. Topical Treatment For Premature EjaculationDespite the rave reviews produced for PSD 502 (see above), the application of chemicals to the penis - however this is achieved - can be messy, indiscreet, and does rather depend on the man's partner going along with the treatment. In addition, there are problems of anorgasmia, inability to ejaculate, and penile numbness (not to mention vaginal numbness). However, oral treatment with Viagra can be helpful when premature ejaculation develops after mild erectile dysfunction, probably because it reduces the anxiety about not getting an erection. Video: How to Delay Climax - EMLA Cream
|
